Palatin Technologies (PTN) Interest Expenses (2010 - 2026)
Palatin Technologies' (PTN) quarterly Interest Expenses came in at $1268.0 in Q1 2026, down 29.36% YoY from $1795.0 in Q1 2025, and up 154.62% on a QoQ basis from $498.0 in Q4 2025.
Palatin Technologies (PTN) Interest Expenses (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 17 years of Interest Expenses data on file, last reported at $1268.0 in Q1 2026.
- Quarterly Interest Expenses fell 29.36% year-over-year to $1268.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7255.0 (up 101.09% YoY) and the FY2025 annual result came in at $70.3 million, up 12.11% from the prior year.
- Interest Expenses rose to $1268.0 in Q1 2026, from $498.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $1.1 million in Q4 2022 to a low of -$679798.0 in Q2 2024.
- A 5-year average of $70404.4 and a median of $3645.0 in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses surged 2023.86% — and 2024, when it slumped 275.3%.
- Tracing PTN's Interest Expenses over 5 years: stood at $1.1 million in 2022, then sank by 99.86% to $1605.0 in 2023, then surged by 136.95% to $3803.0 in 2024, then tumbled by 86.91% to $498.0 in 2025, then soared by 154.62% to $1268.0 in 2026.
- The last three Interest Expenses figures came in at $1268.0 (Q1 2026), $498.0 (Q4 2025), and $2002.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | 1,268.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,268.00 |
| Mar 31, 2026 | 1,268.00 |
| Dec 31, 2025 | 498.00 |
| Dec 31, 2025 | 498.00 |
| Sep 30, 2025 | 2,002.00 |
| Sep 30, 2025 | 2,002.00 |
| Jun 30, 2025 | 3,487.00 |
| Jun 30, 2025 | 3,487.00 |
| Mar 31, 2025 | 1,795.00 |
| Mar 31, 2025 | 1,795.00 |
| Dec 31, 2024 | 3,803.00 |
| Dec 31, 2024 | 3,803.00 |
| Sep 30, 2024 | 10,882.00 |
| Sep 30, 2024 | 10,882.00 |
| Jun 30, 2024 | -679,798.00 |
| Jun 30, 2024 | -679,798.00 |
| Mar 31, 2024 | 1,254.00 |
| Mar 31, 2024 | 1,254.00 |
| Dec 31, 2023 | 1,605.00 |
| Dec 31, 2023 | 1,605.00 |